Janet Woodcock, MD was named Acting Commissioner of Food and Drugs on January 20, 2021.
As Acting Commissioner, Dr. Woodcock oversees the full breadth of the FDA portfolio and execution of the Federal Food, Drug, and Cosmetic Act and other applicable laws. This includes assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices; the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation; and the regulation of tobacco products.
Prior to this appointment, Dr. Woodcock was Director of Center for Drug Evaluation and Research (CDER) at the FDA, until she was asked to lend her expertise to “Operation Warp Speed” for developing therapeutics during the COVID-19 pandemic, such as evaluating the potential benefits of monoclonal antibody treatments for certain COVID-19 patients. From late 2020, she split her time advising “Operation Warp Speed” on advancing COVID-19 therapeutics while also serving as the Principal Medical Advisor to the Commissioner on key priorities on behalf of the Office of the Commissioner. For more information about Dr. Woodcock, please see https://www.fda.gov/about-fda/fda-organization/janet-woodcock-0

Clinical Research as a Care Option (CRAACO), is guided by a dedicated group of advisors from pharma, healthcare, patients and patient advocacy who are passionate about providing patients with the best possible options. CRAACO addresses the value, opportunities, and challenges to integrating clinical research as a care option for the benefit of patients.

https://www.linkedin.com/showcase/clinical-research-as-a-care-option

‍